David Kessler

Recent breakthroughs in medicine, including Revolution Medicines' pancreatic cancer treatment and Eli Lilly's anti-obesity drug, show significant progress in extending patient survival and reducing body weight. These advancements stem from decades of research investment but face challenges like high costs and the need for long-term use.

At the American Society of Clinical Oncology's annual meeting, grief and loss were highlighted alongside cancer research data. Eric Small, the outgoing president, addressed the meeting about his partner Amy Lin, who died from metastatic clear cell ovarian cancer, and featured grief expert David Kessler to discuss compassionate end-of-life care.

Parabilis Medicines has filed to go public under the symbol PBLS. Former FDA commissioner David Kessler expressed confidence in Kyle Diamantas, the new interim FDA chief. The development comes amid increased competition from China in the biotech industry.

Biotech investors' concerns about the Make America Healthy Again movement are fading, and a former FDA head has confidence in the agency's new acting commissioner. The FDA has faced recent tumult, but an inflection point may be nearing. The mood among biotech investors is improving due to decreased political risk.

Former FDA commissioner David Kessler is hopeful that the agency is on a better path under newly appointed acting commissioner Kyle Diamantas. Kessler expressed confidence in Diamantas' ability to serve as a stabilizing force for the agency. The FDA has faced upheaval and high-profile exits recently.

The article discusses the latest on Ebola, including a travel ban and an old vaccine, and mentions STAT's Breakthrough Summit West with various speakers. The summit features former FDA commissioner David Kessler and other notable figures.